close read more

key Figures

21,800 employees

98% of Servier brand-name medicines

active ingredients are synthesized in France.

Over 150 countries

in which the Group’s medicines are distributed

4 therapeutic areas

oncology, cardiometabolism, neuroscience and immuno-inflammation

39 projects

in clinical development, including 17 new molecular entities (July 2022).

16 chemical and pharmaceutical production sites

15 International Centers for Therapeutic Research

and 6 Research centers (3 in France, 1 in Denmark, 1 in Hungary and 1 in the US).

€4.7 billion euros in revenue in 2020/2021

comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines.

More than 20% of revenue from brand-name medicines invested in R&D

each year

34th largest pharmaceutical Group worldwide

and 2nd largest pharmaceutical Group in France[1].

A leader position in cardiology in France

3rd leading pharmaceutical Group in cardiology worldwide and 3rd leading pharmaceutical Group in hypertension worldwide[1].

Participation reached 38.7% of the trade balance surplus in France

in pharmaceuticals and fine chemicals (brand-name medicines).

Key figures as of September 30th, 2021

[1] Source: IQVIA, Analytics Link / World 74 countries – MAT Q1-2022